Expert council discusses the efficacy of disease-modifying drugs and pharmaconutraceuticals in managing chronic back pain, suggesting they should be included in clinical guidelines.
In September 2025, an expert council meeting was held to discuss the role and importance of disease-modifying drugs for osteoarthritis and pharmaconutraceuticals in the treatment of chronic nonspecific back pain. This meeting presented data from studies examining efficacy and safety of bioactive extract and concentrate from small sea fish, chondroitin sulfate, glucosamine and their combinations, as well as some pharmaconutraceuticals in the treatment of musculoskeletal back pain. There is a need to include these agents in clinical guidelines for the management of chronic musculoskeletal back pain for its effective and safe management and prevention.
No takes yet. Share an insight, caveat, or question.
Churyukanov et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: